Pomerantz Law Firm Probes argenx SE Over Investor Claims
Securities law firm Pomerantz LLP has opened an investigation into argenx SE on behalf of shareholders of the NASDAQ-listed biopharmaceutical company.
Pomerantz LLP announced it is investigating potential legal claims on behalf of investors in argenx SE, the biopharmaceutical company traded on NASDAQ under the ticker symbol ARGX, according to a statement released November 5, 2026.
The New York-based securities law firm is advising affected investors to reach out directly to attorney Danielle Peyton for information regarding their rights and potential participation in any forthcoming legal action. Contact details provided by the firm include a dedicated email address and phone line for investor inquiries.
Read more Wirex Launches Tokenized US Stocks for 2 Million Users →
Investigations of this nature by plaintiff-side securities law firms typically precede class-action lawsuits alleging that a company or its executives misled shareholders through false or misleading statements, though the specific allegations underpinning the argenx probe were not detailed in the firm's announcement. Pomerantz LLP is among the more prominent U.S. firms specializing in securities, corporate, and antitrust class-action litigation.
Argenx SE is a global immunology company focused on severe autoimmune diseases and has drawn significant investor attention in recent years due to its flagship product pipeline. Shareholders who sustained losses on ARGX positions and wish to learn more about their legal options are encouraged to contact the firm directly ahead of any potential lead plaintiff deadlines.
Continue reading at All Financial Services & Investing.